CEL-SCI's Multikine® Immunotherapy Produces Significant 14.1% 5-Year Survival Benefit (62.7% Vs 48.6%) in the Group Receiving Surgery Plus Radiotherapy in a Landmark Head and Neck Cancer Phase 3 StudyBusiness Wire • 06/28/21
CEL-SCI Corporation Invites Participants to Pre-Submit Questions for Annual Shareholder MeetingBusiness Wire • 06/25/21
CEL-SCI Corporation to Present at the 2021 H.C. Wainwright BIOCONNECT Virtual ConferenceBusiness Wire • 01/08/21
CEL-SCI Reports Fiscal 2020 Financial Results and Clinical & Corporate DevelopmentsBusiness Wire • 12/30/20
CEL-SCI Corporation to Present at the 13th Annual LD Micro Main Event ConferenceBusiness Wire • 12/14/20
CEL-SCI's LEAPS Peptides Demonstrate Clear Survival Benefit as a Treatment for COVID-19 in Preclinical StudiesBusiness Wire • 12/01/20
CEL-SCI Corporation to Present at H.C. Wainwright 22nd Annual Global Investment ConferenceBusiness Wire • 09/11/20